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Objective: To determine whether statin exposure is associated with decreased cancer and mortality risk 46 
among persons with HIV (PWH) and uninfected persons. Statins appear to have immunomodulatory and 47 
anti-inflammatory effects and may reduce cancer risk, particularly among PWH as they experience 48 
chronic inflammation and immune activation.  49 
Design: Propensity score matched cohort of statin-exposed and unexposed patients from 2002-2017 in 50 
the Veterans Aging Cohort Study (VACS), a large cohort with cancer registry linkage and detailed 51 
pharmacy data. 52 
Methods: We calculated Cox regression hazard ratios (HRs) and 95% confidence intervals (CI) associated 53 
with statin use for all cancers, microbial cancers (associated with bacterial or oncovirus coinfection), 54 
non-microbial cancers, and mortality. 55 
Results: The propensity score-matched sample (N=47,940) included 23,970 statin initiators (31% PWH). 56 
Incident cancers were diagnosed in 1,160 PWH and 2,116 uninfected patients. Death was reported in 57 
1,667 (7.0%) statin-exposed, and 2,215 (9.2%) unexposed patients. Statin use was associated with 24% 58 
decreased risk of microbial associated cancers (HR 0.76; 95% CI 0.69–0.85), but was not associated with 59 
non-microbial cancer risk (HR 1.00; 95% CI 0.92-1.09). Statin use was associated with 33% lower risk of 60 
death overall (HR 0.67; 95% CI 0.63–0.72). Results were similar in analyses stratified by HIV status, 61 
except for non-Hodgkin lymphoma where statin use was associated with reduced risk (HR 0.56; 95% CI 62 
0.38-0.83) for PWH, but not for uninfected (p-interaction = 0.012). 63 
Conclusions: In both PWH and uninfected, statin exposure was associated with lower risk of microbial, 64 
but not non-microbial cancer incidence, and with decreased mortality. 65 
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Beyond their lipid-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme (HMG-70 
CoA) reductase inhibitors, commonly known as statins, have multiple benefits. Statins inhibit conversion 71 
of HMG-CoA to mevalonic acid, an early and major rate-limiting step of cholesterol biosynthesis. In 72 
addition to cholesterol biosynthesis, this pathway also mediates protein prenylation and regulates T cell 73 
cycle progression and function including migration, proliferation and cytotoxic effector responses [1, 74 
2]. Further, statins might interfere with leukocyte trafficking and T cell activation through inhibition of 75 
the beta2 integrin leukocyte function antigen-1 (LFA-1)/intercellular adhesion molecule (ICAM)-1 76 
interaction [3]. Statins therefore have a variety of anti-inflammatory [4] and immune-modulatory [5] 77 
effects and could potentially enhance immune response against invading pathogens and tumor cells [6].  78 
 In the general population, the potential association of statin use with cancer risk and mortality 79 
has been inconsistent. A Dutch analysis of over 3,000 statin-exposed and 17,000 matched unexposed 80 
persons reported statin use was associated with 20% reduction in cancer risk [7]. A Canadian analysis of 81 
over 50,000 patients with acute myocardial infarction found that compared to non-statin users, those 82 
with a high-dose statin prescription at hospital discharge had 25% lower risk of cancer over the following 83 
7 years [8]. Similarly, U.S. Veterans using statins had 25% lower risk of cancer compared to those using 84 
anti-hypertensives in the absence of statins [9]. However, a meta-analysis of 27 studies evaluating the 85 
efficacy of statins in reducing cardiovascular disease showed no association with incidence of, or 86 
mortality from, cancer [10, 11]. The association of statin exposure with decreased site-specific cancer 87 
risk has been observed in some studies [12-16], but not in others [17-20]. A Danish population study 88 
showed an association between statin use at the time of cancer diagnosis and reduced risk of both 89 
cancer-related and all-cause mortality [21]. Reduced cancer-related mortality was observed for all 13 90 
included cancer types. Inconsistent findings in the general population could be related to differences in 91 




accounting for “confounding by indication” is a major concern in most observational studies [22, 23]. We 93 
are unaware of any published randomized controlled trials (RCT) specifically designed for statin 94 
exposure with cancer endpoints. Meta-analyses of trials designed for other endpoints generally 95 
considered all cancers together and found no significant associations between statins and cancer [10, 96 
24].  97 
While associations between statins and cancer risk have been inconsistent in the general 98 
population, statin effects may be particularly pronounced among persons with HIV (PWH), due to long-99 
term effects of HIV viral replication and the prevalence of viral and bacterial coinfections known to 100 
increase cancer risk. Three small studies of PWH found statin use associated with decreased incidence of 101 
AIDS- and non-AIDS-defining cancers [25-27]. Also, statin use has been associated with significantly 102 
lower risk of death in a single center US HIV cohort [28], but non-significantly associated with lower 103 
mortality in the Danish HIV cohort [29].  104 
The effect of statins on cancer incidence has not been compared among PWH and 105 
demographically similar uninfected individuals. Further, analysis of the association of statins with 106 
specific cancer types and mortality in PWH has been limited by small sample size and short follow-up 107 
time. We used the Veterans Aging Cohort Study (VACS), a large cohort of PWH and demographically-108 
matched uninfected individuals receiving care in the Veterans Health Administration (VA), to examine 109 
the effect of statin exposure on the incidence of any cancer, microbial cancers (cancers associated with 110 
bacterial or oncovirus infection), non-microbial cancers, specific cancer types, and with all-cause 111 
mortality. We used a propensity score matched cohort design to reduce the impact of confounding by 112 
indication [30]. We hypothesized that the association of statins with cancer would be strongest among 113 
PWH and for microbial cancers. 114 
METHODS 115 




The VACS is a prospective cohort of all PWH in the VA, the largest integrated healthcare system 117 
in the US. Each newly identified PWH is matched to two uninfected Veterans under VA care at that time 118 
by age, sex, race/ethnicity, year, and the clinical site where they receive care, as described previously 119 
[31]. The full cohort is predominantly male (97%) and about half non-Hispanic black.  120 
Patients have been continuously enrolled each year since 1998 using a validated existing 121 
algorithm from the VA national electronic health record system [32]. The VACS database consists of 122 
detailed demographics, hospital and outpatient diagnoses (recorded using International Classification of 123 
Diseases, Ninth Revision [ICD-9] codes), procedures, laboratory results, and dispensed medications data. 124 
Death date was determined from the VA vital status file, and cancer diagnosis information was linked 125 
from the VA national cancer registry. The VA Connecticut Healthcare System and Yale University 126 
Institutional Review Boards have approved the VACS. 127 
Study population 128 
We identified statin users from October 1, 1998 to September 30, 2015. Statin-exposed persons 129 
were defined as newly-initiating statin use (atorvastatin, fluvastatin, lovastatin, pravastatin, 130 
rosuvastatin, and simvastatin) between fiscal year 2002-2015 and having at least two prescription fills 131 
within 180 days and clinic visits at the following VA clinics: general internal medicine, cardiology, 132 
endocrinology, diabetes, gastroenterology, hypertension, infectious disease, pulmonary, 133 
renal/nephrology, geriatrics, women’s clinic, primary care, and hepatology. These clinics were chosen 134 
because nearly all statin-exposed patients (97.6%) had a visit to one of these clinics in the year prior to 135 
first statin prescription in the VA. Statin regimens used by fewer than 100 patients (pitavastatin, 136 
cerivastatin, and nicostatin) were considered rare. Rare statin regimens and patients with statin 137 
exposure before 2002 were excluded. We randomly selected one outpatient visit date per calendar year 138 




unexposed patients came from the same source population and had an equal opportunity to receive a 140 
statin prescription. 141 
We defined an index date as date of first statin fill or as a randomly chosen clinic date during the 142 
same fiscal year for statin-unexposed persons. Follow-up started 180 days following the index date, for 143 
both exposed and unexposed persons, to prevent immortal time bias (due to the requirement of two 144 
statin fills in 180 days) [33, 34] and ended at the event of interest (cancer diagnosis, death) or the last 145 
follow-up date (last patient interaction in the VA) prior to September 30, 2017.  146 
Study outcomes 147 
Study outcomes included incident cancer diagnosis and all-cause mortality. We linked VACS with 148 
the VA national cancer registry, a database of cancer cases diagnosed and/or treated at the VA. We 149 
mapped International Classification of Diseases for Oncology, third edition (ICD-O-3) [35] topography 150 
and morphology codes from these databases to specific cancer types, consistent with Surveillance, 151 
Epidemiology, and End Results (SEER) algorithms [36]. We classified cancer types into the following 152 
groupings: all cancers, microbial cancers, and non-microbial cancers. Microbial cancers were defined as 153 
cancers associated with either known oncoviruses (cancers of the oral cavity and pharynx, stomach, 154 
anus, liver, cervix, vagina, vulva, penis, Hodgkin lymphoma, non-Hodgkin lymphoma, and Kaposi 155 
sarcoma) or chronic bacterial infection (lung and bronchus), using morphology and detailed topography 156 
(Appendix Table 1). For example, squamous cell carcinoma of the anus is a microbial cancer, whereas 157 
other morphological types of anal cancer are non-microbial. We also examined risk of specific cancers of 158 
interest, with sufficient numbers.  159 
Propensity score model 160 
We used propensity score matching to account for potential confounding by indication. We 161 




of the association between statin use and cancer. We explored a wide range of variables related to 163 
patient demographics, clinical data, laboratory results, hospitalizations, and comorbidities. The final 164 
model included calendar year, demographic variables:  age, gender, race/ethnicity; clinical variables: 165 
comorbid conditions (diabetes, hepatitis C virus [HCV], hepatitis B virus [HBV]), body mass index (BMI), 166 
smoking status, anti-hypertensive medication exposure history; laboratory variables: glucose, FIB-4 167 
(calculated from age, aspartate aminotransferase, platelet count, and alanine aminotransferase), 168 
hemoglobin, cholesterol (LDL, HDL, and total), triglycerides, blood pressure; facility level prescription 169 
patterns, numbers of unique clinic visits in the prior year, and hospitalizations (Appendix Table 2). We 170 
used the measurement prior and closest to the index date for all variables. In the PWH propensity score 171 
model (c-statistic=0.893), we included laboratory values for HIV viral load and CD4 cell count as well as 172 
interactions for LDL cholesterol with HIV viral load and LDL cholesterol with HCV. In the uninfected 173 
model (c-statistic=0.901), we included diabetes medication history and an interaction for diabetes 174 
diagnosis status with LDL cholesterol. 175 
Matching 176 
We matched statin-exposed to unexposed persons using greedy matching algorithm without 177 
replacement [37]. We matched each statin-exposed to one unexposed person within a caliper of 0.20 SD 178 
of the logit of propensity score [37]. The final dataset included only matched statin-exposed and 179 
unexposed persons. We assessed covariate balance before and after matching. Covariates were 180 
considered imbalanced if the standardized difference between statin-exposed and unexposed was >0.1 181 
[38].  182 
Outcome analysis 183 
 We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% 184 




types, and mortality. We ran three sets of models, first including all patients and then stratified by HIV 186 
status. We examined whether the association between statins and cancer varied by HIV status in a 187 
model with all patients, adjusting for HIV, and noted if there was a significant HIV and statin interaction.  188 
We calculated standardized differences with Stata version 14.2 (StataCorp LLC, College Station, 189 
Texas). All other analyses were conducted using SAS version 9.4 (SAS Institute, Inc. Cary, North Carolina). 190 
 We conducted sensitivity analyses examining the microbial cancer group definition by 191 
calculating the HR estimates for the microbial and non-microbial cancers with and without lung cancer. 192 
We also calculated HR estimates by statin type at initiation (Simvastatin versus all others). We used the 193 
Benjamini-Hochberg method for multiple-comparison corrections [39]. 194 
RESULTS 195 
 Among VACS participants, there were 12,153 PWH and 34,561 uninfected statin initiators during 196 
the study period (Table 1, Appendix Figure 1). There were 27,876 PWH and 46,642 uninfected patients 197 
without a statin prescription fill in the VA health system among patients alive in the cohort during the 198 
study follow-up period. Statin-exposed patients were older (mean age 54.0 years for PWH, 53.1 years 199 
for uninfected) than patients without a statin prescription (mean age 49.0 years for PWH, 48.4 years for 200 
uninfected).  201 
In the unmatched sample, the median propensity score among statin-exposed patients was 0.24 202 
for PWH and 0.38 for uninfected patients, and among patients not exposed to statins was 0.015 for 203 
PWH and 0.021 for uninfected patients (Appendix Figure 2). After matching, the median propensity 204 
score was 0.13 for PWH and 0.06 for uninfected for both statin-exposed and unexposed patients. All 205 
covariate standardized differences were less than 0.1 indicating no imbalance between exposed and 206 
unexposed  (Table 1). Statin exposed patients who did not have a propensity score match were excluded 207 




unmatched statin exposed patients (Appendix Table 3). Both PWH and uninfected unmatched patients 209 
were less likely to have hepatitis C, diabetes, and index visit during later years compared to propensity 210 
score matched patients.  211 
The propensity score-matched sample (N=47,940) included 23,970 statin initiators (7,335 PWH 212 
and 16,635 uninfected) and 23,970 statin-unexposed patients (Table 1). Median follow-up time was 5.7 213 
(IQR: 3.0-9.0) years for PWH and 7.1 (IQR: 3.8-10.4) years for uninfected patients. Mean age was 52-53 214 
years old for the propensity score matched patients. Simvastatin was the most commonly prescribed 215 
statin, representing 63.5% of all first statin prescriptions. 70.8% of statin-exposed patients took 216 
simvastatin, followed by atorvastatin (54.3%), pravastatin (33.5%), rosuvastatin (13.7%), lovastatin 217 
(6.7%), and fluvastatin (5.5%) during the entire follow-up period, including regimen changes. Median 218 
duration of statin use was 3.0 years (interquartile range [IQR]: 1.2-5.8 years) overall. Incident cancers 219 
were diagnosed in 1,160 PWH (22.8 cancers/1,000 person-years) and 2,116 uninfected patients (17.4 220 
cancers/1,000 person-years). The most common cancer types were lung and prostate cancer. Death was 221 
reported in 1,667 (7.0%) statin-exposed and 2,215 (9.2%) unexposed persons.  222 
Overall, statin use was associated with 11% reduced risk of any cancer (HR 0.89; 95% CI 0.83–223 
0.95) and 24% decreased risk of microbial cancers (HR 0.76; 95% CI 0.59–0.85) (Figure 1). Statin use was 224 
not associated with non-microbial cancers (HR 1.00; 95% CI 0.92–1.09). Statin use was also associated 225 
with lower risk of death (HR 0.67; 95% CI 0.63–0.72). The association between statin use and reduced 226 
cancer risk for both PWH and uninfected patients was strongest for hepatocellular carcinoma (HR 0.54; 227 
95% CI 0.42-0.69) and HPV-associated squamous cell carcinomas of the oral cavity and pharynx (HR 0.60; 228 
95% CI 0.40-0.90). Results were similar in analyses stratified by HIV, with a few exceptions. For PWH, 229 
statin use was associated with reduced non-Hodgkin lymphoma risk (HR 0.56; 95% CI 0.38-0.83); but not 230 
for uninfected patients (p for interaction = 0.012). Also, there was reduced risk of lung and bronchus 231 




(HR 0.93; 95% CI 0.73–1.20); however, the confidence interval was wider for PWH and the finding was 233 
not significant. Among PWH, statin use was associated with 51% reduced Kaposi sarcoma risk (HR 0.49; 234 
95% CI 0.26-0.92). There were no Kaposi sarcoma cases among uninfected patients. 235 
In a sensitivity analysis removing lung cancer from the microbial cancer category (Appendix 236 
Table 4). This led to minimally stronger association with statin exposure (0.76 vs 0.74). For non-microbial 237 
cancers the association with statin exposure remained close to 1. Simvastatin was the dominant initial 238 
statin type prescribed through 2012 (Appendix Figure 3). We therefore compared results for patients 239 
who initiated Simvastatin versus the other statin types. The hazard ratio patterns were similar with the 240 
original analysis except where there were few events, resulting in wide confidence intervals (oral 241 
cavity/pharynx and anal cancers, Appendix Figure 4). 242 
DISCUSSION 243 
In this large cohort of PWH and demographically similar uninfected patients, statin exposure 244 
was associated with 11% lower risk of any cancer compared to propensity score matched unexposed 245 
patients. The strongest associations were for microbial cancers: liver and oral/pharyngeal cancers for 246 
both PWH and uninfected, non-Hodgkin lymphoma and Kaposi sarcoma among PWH, and lung cancer 247 
among uninfected patients. The decreased risk was generally similar among PWH and uninfected 248 
patients. When cancers were grouped, statin exposure was associated with decreased cancer risk 249 
among microbial (24% reduced risk) but not among non-microbial cancers. This finding suggests that 250 
statins may specifically interfere with the pathogenesis of microbial cancers which are more common 251 
among PWH.   252 
Microbial co-infection, chronic inflammation, and immune dysfunction are potent 253 
environmental stimuli for oncogenesis. The prevalence of co-infection with HCV, HBV, Epstein Barr virus, 254 




AIDS-defining malignancies [43-45, 47-53] is higher among PWH than in the general population, 256 
accounting for behavioral risk factors and excess cancer risk remaining after long-term viral suppression 257 
[54]. Persistent inflammation and immune dysfunction in HIV patients – even in the context of long-term 258 
suppressive antiretroviral therapy (ART) [55, 56] – has been associated with increased risk of non-AIDS 259 
complications including cancer [57-59].   260 
Intriguingly, statins have both antimicrobial and anti-inflammatory effects. Statins have in vitro 261 
antiviral activity against human cytomegalovirus [60], dengue virus [61, 62], and HIV-1 [63], and statin 262 
use was associated with reduced risk of virologic rebound in PWH on suppressive ART [64]. Also, statins 263 
may differ in their effect(s) on inflammation and immune activation [65], and as a result, have different 264 
effects on cancer risk. Thus, our finding that statin exposure is associated with decreased risk of 265 
microbial cancers has biologic plausbility.  266 
Previous studies have suggested a possible dose-response relationship, with longer duration and 267 
higher doses of statin use being associated with lower risk of cancer. In the Dutch study, the effect of 268 
statin was observed only with longer duration of statin use (more than 4 years) [7], while in the 269 
Canadian study, compared to statin-unexposed persons, risk of cancer was lower among high-dose 270 
statin-exposed persons (HR: 0.75; 95% CI: 0.60 – 0.95) and marginally lower among low-dose statin-271 
exposed persons (HR: 0.89; 95% CI: 0.75 – 1.07). This could explain, in part, the inconsistent findings of 272 
published studies, as most did not account for duration of statin exposure or adherence.  273 
We found that statin exposure was associated with 33% lower risk of all-cause mortality. 274 
Although we did not examine cause of death, it is possible that some of the mortality reduction was 275 
cancer-related mortality. However, the magnitude of mortality benefit suggests that it might not be 276 
entirely mediated through reduced cancer risk or cancer-related mortality. Beyond risk of cancer 277 
incidence, statins have been shown to be associated with decreased cancer mortality. In the Danish 278 




despite lack of association with cancer incidence [29]. Also, results from a small HIV cohort that showed 280 
statin exposure associated with lower risk of death, the majority of deaths were cancer-related [28].  281 
Our findings have important clinical implications as microbial malignancies are a leading cause 282 
of mortality in the aging population, and cancer-related deaths are increasing in proportion in many HIV 283 
cohorts [66, 67]. Rates of malignancies continue to be significantly higher among PWH [54], thus further 284 
improvement in HIV survival will likely require biomedical interventions such as statins, in addition to 285 
cancer prevention and screening strategies. 286 
Strengths of our study include use of a large national cohort of PWH in the modern ART era and 287 
demographically similar uninfected persons followed over a 16-year period, with linked cancer registry 288 
data with low rates of misclassification and longitudinal pharmacy dispensing records. This allowed for 289 
sufficient cancer and death events to accrue to examine the relationship between statin exposure and 290 
both cancer risk and mortality. Further, we used propensity score matching which allowed us to control 291 
for confounding by indication, which is a significant hurdle in pharmacoepidemiological studies using 292 
real-world data [22, 30]; however, there is always potential for residual and unmeasured confounding. 293 
Propensity score matching allows the use of an observational cohort to emulate a randomized 294 
controlled trial (RCT) by 1) calculating the propensity score to establish the strength of the indication 295 
(criteria that would have been used for inclusion in an RCT) and 2) matching on the propensity score to 296 
balance treatment arms by potential confounders, both known and unknown. RCTs often exclude older 297 
and sicker patients; however, our study population and results are more generalizable due to a wider 298 
array of patients than typically recruited in an RCT. 299 
Limitations of our study include a predominantly male (97%) population, so it is unclear if our 300 
findings are generalizable to women. Cancers have long latency periods therefore, longer follow-up may 301 
be needed to see the full effects of statins in cancer prevention. Nonetheless, we did see signal in this 302 




number of statistical tests; however, the 13 cancer types and groups were selected from a priori 304 
hypotheses. Using the Benjamini-Hochberg method with a false discovery rate threshold of 25%, our 305 
findings remain significant (for any cancer, microbial cancers, oral cavity and pharynx cancer, 306 
hepatocellular carcinoma, lung cancer, Kaposi sarcoma). Non-Hodgkin lymphoma would also meet the 307 
threshold for significance. Finally, we did not determine specific causes of mortality and therefore 308 
cannot determine whether the associations of statins with decreased cancer risk and decreased 309 
mortality are related. Cancer incidence data was obtained from the VA national registry, therefore 310 
cancers diagnosed and treated outside the VA system are unlikely to have been ascertained. However, 311 
as patients treated with statins in VA care are more likely to have been engaged in primary care within 312 
the VA (and thereby diagnosed with cancer within the VA), this would bias the statin arm towards more 313 
cancer diagnoses, thereby strengthening the associations noted in our findings. We were only able to 314 
propensity score match 60% of PWH and 48% of uninfected statin users, thus our findings may not apply 315 
to all statin users. However, this is similar to what happens in randomized trials that apply inclusion and 316 
exclusion criteria.  317 
In conclusion, we observed that statin use was associated with at least 10% lower risk of cancer 318 
in PWH and uninfected patients, and an even greater (>30%) decreased risk of all-cause mortality. Statin 319 
exposure was associated with lower risk of microbial, but not non-microbial, cancer. These findings were 320 
largely consistent between PWH and uninfected patients. Prospective, randomized studies, like the 321 
REPRIEVE trial, which is examining the efficacy of statins for the primary prevention of major adverse 322 
cardiovascular events in PWH with low to moderate traditional risk [68] may be able to assess the effect 323 
of specific statins on chronic inflammation/immune activation and HIV persistence. However, 324 
REPRIEVE’s main study endpoint is not cancer, therefore, we encourage future research to examine the 325 
reproducibility of our findings in both clinical trials and observational cohorts. 326 
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Table 1. Baseline characteristics among statin-exposed and unexposed persons in the pre-matched and propensity score-matched patients 
and standardized differences in the propensity-score-matched patients 
  All patients (pre-matched) Propensity score matched 










  N=12,153 N=27,876 N=34,561 N=46,642 N=7,335 N=7,335 Std N=16,635 N=16,635 Std 
    N % N % N % N % N % N % diff N % N % diff 
Age Mean +/-st dev (years) 54.0 9.4 49.0 11.3 53.1 9.2 48.4 12.3 53.8 9.5 53.1 9.4 -0.08 53.2 9.8 52.2 9.9 -0.10 
Race/ethnicity Non-Hispanic white 5,467 45.0 10,319 37.0 13,967 40.4 18,164 38.9 3,114 42.5 3,080 42.0 0.02 6,705 40.3 6,625 39.8 0.02 
  Non-Hispanic black 5,369 44.2 14,017 50.3 16,343 47.3 22,353 47.9 3,419 46.6 3,460 47.2  7,932 47.7 7,979 48.0  
  Hispanic 949 7.8 2,260 8.1 3,086 8.9 3,806 8.2 580 7.9 562 7.7  1,459 8.8 1,446 8.7  
  Other/unknown 368 3.0 1,279 4.6 1,165 3.4 2,319 5.0 222 3.0 233 3.2  539 3.2 585 3.5  
Sex Female 327 2.7 855 3.1 876 2.5 1,738 3.7 216 2.9 234 3.2 0.01 478 2.9 484 2.9 <0.01 
  Male 11,826 97.3 27,020 96.9 33,685 97.5 44,904 96.3 7,119 97.1 7,101 96.8  16,157 97.1 16,151 97.1  
Hepatitis C* HCV negative 8,991 74.0 16,815 60.3 25,948 75.1 29,099 62.4 5,158 70.3 5,133 70.0 0.03 11,997 72.1 11,765 70.7 0.04 




  HCV exposure 735 6.0 2,000 7.2 1,160 3.4 1,660 3.6 464 6.3 434 5.9  591 3.6 606 3.6  
  Never tested in the VA 305 2.5 1,395 5.0 4,172 12.1 8,902 19.1 166 2.3 192 2.6  2,028 12.2 2,205 13.3  
Hepatitis B* HBV negative 10,280 84.6 22,162 79.5 18,737 54.2 23,876 51.2 6,177 84.2 6,143 83.7 0.03 9,146 55.0 8,978 54.0 0.02 
  HBV positive 424 3.5 1,031 3.7 134 0.4 209 0.4 284 3.9 292 4.0  72 0.4 81 0.5  
  HBV acute resolved 140 1.2 349 1.3 78 0.2 116 0.2 94 1.3 83 1.1  43 0.3 43 0.3  
  Unconfirmed HBV 81 0.7 324 1.2 53 0.2 91 0.2 49 0.7 60 0.8  20 0.1 24 0.1  
  Never tested in the VA 1,228 10.1 4,009 14.4 15,559 45.0 22,350 47.9 731 10.0 757 10.3  7,354 44.2 7,509 45.1  
BMI Under/normal weight (<30) 8,668 71.3 21,122 75.8 16,596 48.0 26,783 57.4 5,348 72.9 5,419 73.9 0.03 8,848 53.2 9,198 55.3 0.05 
  Overweight (30-34.9) 2,152 17.7 2,914 10.5 9,964 28.8 8,948 19.2 1,283 17.5 1,264 17.2  4,449 26.7 4,372 26.3  
  Obese (≥ 35) 1,027 8.5 1,122 4.0 7,003 20.3 4,901 10.5 562 7.7 513 7.0  2,892 17.4 2,623 15.8  
  Unknown 306 2.5 2,717 9.7 998 2.9 6,010 12.9 142 1.9 139 1.9  446 2.7 442 2.7  
Smoking Non-smoker 3,583 29.5 7,261 26.0 10,194 29.5 13,751 29.5 2,068 28.2 2,045 27.9 0.05 4,905 29.5 4,831 29.0 0.06 
  Current 6,031 49.6 15,724 56.4 16,746 48.5 24,207 51.9 3,826 52.2 3,945 53.8  8,312 50.0 8,524 51.2  
  Former 2,385 19.6 3,654 13.1 7,267 21.0 6,700 14.4 1,352 18.4 1,236 16.9  3,245 19.5 3,017 18.1  
  Unknown 154 1.3 1,236 4.4 354 1.0 1,984 4.3 89 1.2 109 1.5  173 1.0 263 1.6  
Diabetes No  9,509 78.2 25,804 92.6 24,281 70.3 42,879 91.9 5,920 80.7 6,085 83.0 0.06 13,283 79.8 13,846 83.2 0.09 




Year of 2002-2003 1,852 15.2 5,172 18.6 6,339 18.3 7,230 15.5 818 11.2 818 11.2 <0.01 2,094 12.6 2,094 12.6 <0.01 
Index visit  2004-2006 2,905 23.9 5,203 18.7 10,482 30.3 9,228 19.8 1,506 20.5 1,506 20.5  4,068 24.5 4,068 24.5  
  2007-2009 2,861 23.5 4,556 16.3 8,495 24.6 9,093 19.5 1,641 22.4 1,641 22.4  4,119 24.8 4,119 24.8  
  2010-2012 2,554 21.0 5,268 18.9 5,658 16.4 11,108 23.8 1,713 23.4 1,713 23.4  3,492 21.0 3,492 21.0  
  2013-2015 1,981 16.3 7,676 27.5 3,587 10.4 46,642 100.0 1,657 22.6 1,657 22.6  2,862 17.2 2,862 17.2  
HIV-RNA ≤ 400 7,343 60.4 11,764 42.2         4,577 62.4 4,432 60.4 0.05          
  >400 1,536 12.6 6,926 24.8         1,054 14.4 1,057 14.4           
  Unknown 3,274 26.9 9,185 33.0         1,704 23.2 1,846 25.2           
CD4  ≥500 4,317 35.5 7,182 25.8         2,754 37.5 2,564 35.0 0.06          
  350-499 2,006 16.5 3,811 13.7         1,263 17.2 1,243 16.9           
  200-349 1,658 13.6 3,726 13.4         1,025 14.0 1,051 14.3           
  0-199 851 7.0 3,862 13.9         557 7.6 605 8.2           
  Unknown 3,321 27.3 9,294 33.3         1,736 23.7 1,872 25.5           
Abbreviations: Std diff = standardized difference, HCV = hepatitis C virus, HBV = hepatitis B virus, BMI = body mass index 
*Definitions: HCV negative, negative HCV antibody test result(s) only; Chronic HCV, positive HCV RNA test; HCV exposure, positive HCV antibody 
test, but negative or unknown HCV RNA test; Never tested in the VA, no HCV laboratory test results available from the VA (it is possible that 




HBV negative, negative HBV surface antigen test result(s) only; HBV positive, at least two positive HBV surface antigen tests over 6 months apart; 
HBV acute resolved, positive HBV surface antigen test followed by only negative test results; Unconfirmed HBV, one positive HBV surface antigen 
test not confirmed with additional testing; Never tested/unknown, no HBV laboratory test results available. 
 
Figure 1. Propensity score-matched hazard ratios (statin-exposed versus unexposed) for cancer 
groups*, specific cancer types, and mortality 
 
* Microbial cancers include: human papillomavirus (HPV)-related oral cavity and pharynx squamous cell 
carcinoma (SCC), anal SCC, hepatocellular carcinoma (HCC); cancers of the stomach, lung, cervix, vulva, 
vagina, and penis; Hodgkin lymphoma, non-Hodgkin lymphoma, and Kaposi sarcoma 
† P-value for HIV*statin interaction in combined model with HIV and uninfected patients 
‡ Results presented for PWH only because there were only 6 anal squamous cell carcinoma and 0 Kaposi 




SUPPLEMENTAL DIGITAL CONTENT 






code ICD-O-3 morphology 





C01.9 base of tongue  
C02.4 lingual tonsil  




anterior surface of 
epiglottis  
C14.0 pharynx NOS  
C14.2 Waldeyer ring  
8050-8084, 8094 SCC 
8121 Schneiderian carcinoma 
8123 basaloid carcinoma 
8010 carcinoma, NOS 
 Anal SCC Human 
papillomavirus 
C21.0-C21.8 anus and 
anal canal 
C20.9 rectum 
8050-8084, 8094 SCC 
8123 basaloid carcinoma 
8124 cloacogenic carcinoma 




Hepatitis C virus, 
hepatitis B virus 
C22.0 liver 8170-8180 hepatocellular carcinoma 
 Lung and 
bronchus 
Pneumonia C34.0-C34.9 Excluding 9050-9055, 9140, 9590-9992 
 
 Vagina SCC Human 
papillomavirus 
C52.9 vagina 8050-8084, 8094 SCC 
8123 basaloid carcinoma 
8010 carcinoma, NOS 
 Vulva SCC Human 
papillomavirus 
C51.0-C51.9 vulva 8050-8084, 8094 SCC 
8123 basaloid carcinoma 
8010 carcinoma, NOS 
 Penis SCC Human 
papillomavirus 
C60.0-C60.9 penis 8050-8084, 8094 SCC 
8123 basaloid carcinoma 
8010 carcinoma, NOS 
 Non-Hodgkin 
lymphoma 
Epstein-Barr virus  9590-9597, 9670-9671, 9673, 9675, 9678-
9680, 9684, 9687-9691, 9695, 9698-9702, 
9705, 9708-9709, 9712, 9714-9719, 9724-
9729, 9735, 9737-9738, 9811-9818, 9823, 









 9140 Kaposi sarcoma 
ICD-O-3 = International Classification of Diseases for Oncology, Third Edition; NOS = not otherwise specified; 
SCC = squamous cell carcinoma 
* Only for anal sites (C21.0-C21.8), not rectum (C20.9). 
 
Appendix Table 2. Variables considered for propensity score model. X indicates included in final 
model. 
Category Variable HIV model Uninfected model 
 Calendar year X X 
Demographics Age (linear and quadratic)  X X 
 Sex X X 
 Race/ethnicity X X 
Healthcare utilization Medicare utilization   
 Hospitalizations X X 
 Clinic visits X X 
Comorbid conditions Diabetes X X 
 Hepatitis C virus  X X 
 Hepatitis B virus X X 
 BMI X X 
 Smoking status   
Laboratory tests ALT   
 AST   
 Hemoglobin X X 
 Platelets   
 Creatinine   
 eGFR   
 CD4 X  
 CD8   
 CD4/CD8 ratio   
 HIV RNA (viral load) X  
 FIB-4 X X 
 Total cholesterol X X 
 LDL cholesterol X X 
 HDL cholesterol X X 
 Triglyderides X X 
 Fasting glucose X X 
 Blood pressure X X 
Medications Anti-hypertensives X X 
 Diabetes   X 
 Benzodiazepine   
 Epilepsy   
 Other lipid lowering drugs   
Interactions LDL*HIV-RNA X  
 LDL*HCV X  
 Diabetes*LDL  X 
Facility level Prescription patterns X X 
Abbreviations:  BMI = body mass index, ALT = alanine aminotransferase , AST = aspartate 
aminotransferase, eGFR = estimated glomerular filtration rate, FIB-4 = fibrosis-4 index, HCV =  hepatitis C 
virus
